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Tobacco smoking is widespread behavior in Qatar and worldwide and is considered
one of the major preventable causes of ill health and death. Nicotine is part of
tobacco smoke that causes numerous health risks and is incredibly addictive; it binds
to the α7 nicotinic acetylcholine receptor (α7nAChR) in the brain. Recent studies
showed α7nAChR involvement in the initiation and addiction of smoking. Kynurenic
acid (KA), a significant tryptophan metabolite, is an antagonist of α7nAChR. Inhibition
of kynurenine 3-monooxygenase enzyme encoded by KMO enhances the KA levels.
Modulating KMO gene expression could be a useful tactic for the treatment of
tobacco initiation and dependence. Since KMO regulation is still poorly understood,
we aimed to investigate the 5′ and 3′-regulatory factors of KMO gene to advance our
knowledge to modulate KMO gene expression. In this study, bioinformatics methods
were used to identify the regulatory sequences associated with expression of KMO.
The displayed differential expression of KMO mRNA in the same tissue and different
tissues suggested the specific usage of the KMO multiple alternative promoters.
Eleven KMO alternative promoters identified at 5′-regulatory region contain TATA-
Box, lack CpG Island (CGI) and showed dinucleotide base-stacking energy values
specific to transcription factor binding sites (TFBSs). The structural features of regulatory
sequences can influence the transcription process and cell type-specific expression. The
uncharacterized LOC105373233 locus coding for non-coding RNA (ncRNA) located on
the reverse strand in a convergent manner at the 3′-side of KMO locus. The two genes
likely expressed by a promoter that lacks TATA-Box harbor CGI and two TFBSs linked
to the bidirectional transcription, the NRF1, and ZNF14 motifs. We identified two types
of microRNA (miR) in the uncharacterized LOC105373233 ncRNA, which are like hsa-
miR-5096 and hsa-miR-1285-3p and can target the miR recognition element (MRE)
in the KMO mRNA. Pairwise sequence alignment identified 52 nucleotides sequence
hosting MRE in the KMO 3′ UTR untranslated region complementary to the ncRNA
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LOC105373233 sequence. We speculate that the identified miRs can modulate the
KMO expression and together with alternative promoters at the 5′-regulatory region of
KMO might contribute to the development of novel diagnostic and therapeutic algorithm
for tobacco smoking.
Keywords: KMO, kynurenine 3-monooxygenase, gene expression, alternative promoters, non-coding RNA,
nicotine, α7nAChR, kynurenic acid
INTRODUCTION
Morbidity and mortality caused by smoking behavior are
avoidable. Bioinformatics and genomics studies can aid in
tobacco cessation and treatment. The targets for nicotine are the
nicotinic acetylcholine receptors (nAChRs; Mineur and Picciotto,
2008). Inherited genetic variations in nAChRs, α, and β nAChRs
could predict response to smoking cessation therapy (Wassenaar
et al., 2011; Broms et al., 2012; Zhu et al., 2014). Variants of α
and β nAChRs genes involved in the behavioral and cognitive
performance identify patients’ benefit from personalized smoking
cessation intervention and as markers for lung cancer diagnosis
(Chen and Bierut, 2013; Chen et al., 2015; Pérez-Rubio et al.,
2016; Chen L.S. et al., 2018). Furthermore, variants of the
CHRNA7 locus encoding the α7nAChR are linked to smoking
behavior and engaged in the initiation of smoking in healthy
individuals (Brunzell et al., 2015).
The liability to smoking initiation, nicotine dependence, and
intervention encouraged us to study the unexplored genomic and
epigenomic regulatory factors of kynurenine 3-monooxygenase
gene, KMO. The gene linked to several neuropsychiatric diseases
by modulating KA cellular levels (Erhardt et al., 2017). The
KMO gene involvement in neurological disorders identified in
Huntington disease and schizophrenia (Amaral et al., 2013).
Also, it is worth mentioning that the α7nAChRs notably
associated with smoking habit in individuals with schizophrenia
(Brunzell et al., 2015), prepulse inhibition of startle, and cognitive
function, which can be enhanced by nicotine (Pinnock et al.,
2015). Besides the importance of KMO in clinical research
of neurological ailments, there is a potential for using the
KMO gene for treating tobacco addiction and cessation. The
kynurenine 3-monooxygenase enzyme has a significant role in
tryptophan metabolism, kynurenine pathway, and the availability
of kynurenic acid (KA) (Albuquerque and Schwarcz, 2013).
During past two decades, a series of studies showed Ro 61-8048,
kynurenine 3-monooxygenase inhibitor, a potential therapeutic
target for neurodegenerative and neurologic disorders and
promoted increased levels of the KA in the brain that reduced
the cannabinoid abuse and prevented relapse (Röver et al.,
1997; Justinova et al., 2013; Secci et al., 2017; Gao et al.,
2018). Intriguingly, the KA is an antagonist of α7 nicotinic
acetylcholine receptors (α7nAChRs; Justinova et al., 2013). Even
though a recent study showed that kynurenine 3-monooxygenase
inhibition by Ro 61-8048 is promising for the treatment of
nicotine addiction (Secci et al., 2017), there could also be
genomic approaches for this problem. There are no data on the
precise mode of regulatory factors associated with modulation
of KMO expression and their potential use in the treatment of
tobacco initiation and addiction. Thus, it is vital to gain a better
understanding of the KMO genomic regulatory components
associated with the control of the expression. We noticed
several promoters in the databases for KMO gene, but no
information is available on the regulatory elements involved in
the KMO expression. For example, transcription factor binding
sites (TFBSs) consensus motifs, CpG Islands (CGIs), and the
structural features of the KMO alternative promoters. Also,
we speculated the potential involvement of the non-coding
RNA (ncRNA) LOC105373233 locus in the regulation of KMO
expression. LOC105373233 locus is the convergent pair of the
KMO gene. Better knowledge of the genomic and epigenomic
features of KMO can promote novel approaches to modulate
KMO expression by genome editing methods. Such approaches
could be utilized to modulate KA levels and can be used as
biomarkers and targets for tobacco smoking cessation therapy.
In this study, we aimed to investigate the KMO regulatory
factors to advance our knowledge to control the KMO gene
expression. We investigated the motifs of the TFBSs and CGIs
in the KMO alternative promoters. Also, we investigated the
structural features of KMO regulatory sequences analyzed by
dinucleotide stacking energy, and potential influence of the
ncRNA uncharacterized LOC105373233 locus mapped at KMO
3′-region on the expression of KMO gene.
MATERIALS AND METHODS
Genomic Context of KMO Regulatory
Region
The alternative promoters and genomic features of KMO gene
searched using genomics databases shown in Supplementary
Table S1. The tools in the databases used to analyze the
regulatory sequences. Identifying the local similarities between
two sequences analyzed by a rigorous algorithm based on
the LALIGN application of the EMBOSS Matcher tool. Data
from biogps.org used to vindicate our hypothesized approach
that variations in the human KMO gene expression in various
tissues take advantage of specific regulatory elements located
in the alternative promoters of KMO gene. Expression values
from Affymetrix chips relate to fluorescence intensity; the
biogps.org uses gcrma (Wu et al., 2013, 2016). The biogps.org
database gives the minimum of two measurements for each
tissue. Neural Network Promoter Prediction (Reese, 2001) and
Promoter2.0 Prediction Server (Knudsen, 1999) used to predict
KMO promoters at the 5′-side of the KMO gene. The map sites of
the KMO alternative promoters and other regulatory sequences
updated to hg38 version of human genome sequence by using the
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BLAT tool of UCSC Genome Browser. The 5′ and 3′ UTR regions
of the KMO mRNA analyzed by the UCSC Genome Browser
sequence tools.
Analysis of Functional and Structural
Regulatory Features of KMO Promoters
The motifs of 20 TFBSs, namely: TATA-box (TATAWA), INR
(YYANWYY), DTIE (GBBRDNHGG), BRE (SSRCGCC), DPE
(RGWCGTG), M3 (SCGGAAGY), M22 (TGCGCANK), HIF
(RCGTG), EBF3 (CCCNNGGG), Sox (WWCAAWG), P53
(RRRCWWGY), Oct4 (TTTKSWTW), PU.1 (GAGGAA), Nanog
(SRSSATTANS), c-myc (CACRTG), MAD (CCGNCGCG), GAF
(GAGAG), and GATA (WGATAR), were analyzed in the
KMO alternative promoters (Yang et al., 2007; Al-Obaide
et al., 2015, 2016; Marbach-Bar et al., 2016). JASPAR 2018
database was used to search for the TFBSs of ZNF143
and NRF1 (Khan et al., 2018). CGIs in the alternative
promoters identified following the reported parameter set and
equation reported by Gardiner-Garden and Frommer (1987)
and CGI tools (Supplementary Table S1). The dinucleotide
base-stacking energy values were calculated from values of
dinucleotide base-stacking energy provided by Ornstein et al.
(1978).
Identification of lncRNA-miR and
KMO-MRE
The unreported microRNA (miR) sequences of the predicted
uncharacterized lncRNA LOC105373233 ncRNA, NCBI
Reference Sequence: XR_949327.1, were identified by the
miRBase search tool (Griffiths-Jones et al., 2006; Kozomara and
Griffiths-Jones, 2014). The miR recognition elements (MREs) in
the KMO mRNA, NM_003679.4 identified by RNA22 v2 miR
target detection tool (Miranda et al., 2006). The miR binds to the
target MRE.
Statistical Analysis
The statistical analyses of the obtained results were achieved
using Excel software. The t-test was used for analysis of two
independent samples, whereas one-way ANOVA was used to
analyze the differences among group means of more than two
examples. A significant difference was shown by p ≤ 0.05.
RESULTS
Kynurenic Acid Metabolic Pathway and
Genomic Context of KMO and ncRNA
Uncharacterized LOC105373233 Loci
Kynurenic acid is the product of kynurenine pathway
(Figure 1A). Kynurenine 3-monooxygenase encoded by
KMO gene is a crucial enzyme in the metabolic regulation of
the KA levels. Albuquerque and Schwarcz (2013) and Secci
et al. (2017) showed that KA is an antagonist of α7nAChRs in
the brain. The Ro 61-8048, a kynurenine 3-monooxygenase
inhibitor increases brain KA concentrations and might
have applications in the treatment of nicotine addiction
(Figure 1B) (Röver et al., 1997; Justinova et al., 2013; Secci
et al., 2017). Thus, we hypothesized inhibiting or more precisely
modulating KMO gene expression by genomic and epigenetic
approaches could be utilized to enhance the availability
of KA.
The human KMO locus, NCBI Gene ID: 8564, occupies
a region of 63,765 bps on the forward strand of the long
arm of chromosome 1 mapped to cytogenetic location 1q43
at GRCh38/hg38 genomic coordinates: chr1: 241,531,883-
241,595,647 (Figure 1C). The KMO mRNA transcript,
NM_003679.4, composed of 15 exons (Supplementary Table S2).
The KMO locus is convergently paired at the reverse strand
of 3′-region with an ncRNA uncharacterized LOC105373233
locus (Figure 1C). The ncRNA locus located at genomic
coordinates: chr1:241,585,025-241,588,836 and occupies a
genomic region of 3,811 bps, which mapped in the KMO
region between exons 10 and 13 (Supplementary Figure S1).
The uncharacterized LOC105373233 transcript XR_949327
composed of 422 bps. The Ensembl database showed three exons
in the genomic space of the LOC105373233 (Supplementary
Table S3).
Differential Activities of Alternative
Promoters in Modulating KMO mRNA
Expressions
We extrapolated KMO expression data from the biogps.org to
show the variation in KMO gene expression at mRNA levels
in normal tissues. The analysis of KMO mRNA expression
in 11 types of human tissues showed variable expressions
(Supplementary Figure S2). The statistical analysis indicated that
there is a significant difference in the KMO expression among
the 11 selected adult normal human tissues, p-value < 0.05. The
observed variation in the KMO mRNA expressions in various
tissues is an indication of the differential usage of a specific
alternative promoter. Thus, alternative promoters can modulate
KMO expression differentially in various types of cells and
tissues according to cellular environments or relevant regulatory
factors. This assumption does not ignore the tasks played by
other regulatory factors associated with KMO expression. We
identified 11 KMO alternative promoters reported in EPD,
TRED, and FANTOM5 databases. EPD and TRED databases
showed one and two promoters, respectively, whereas FANTOM
5 database showed eight promoters (Supplementary Table S4).
The identified alternative promoters are located on chromosome
1 at the 5′-side of KMO-exon 1. Our analysis showed
that the 11 alternative promoters’ sequences, AP1–AP11, are
overlapping. The KMO alternative promoters reported in the
FANTOM 5 displayed variable expression in the brain. The
p1@KMO1 exhibited the highest expression compared with
other KMO alternative promoters. FANTOM 5 uses CAGE (Cap
Analysis Gene Expression) protocol, which identify the exact
transcription start sites (TSSs). If the KMO is actively expressed
because p1@KMO1 expression, suitable genomic methods can
silence the p1@KMO1 (see section “Discussion”). Thus, the
promoter can be considered a candidate to lower KMO gene
expression.
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FIGURE 1 | (A) Kynurenic acid (KA) is the product of kynurenine pathway, the central metabolite of the tryptophan metabolism. (B) Inhibition of kynurenine
3-monooxygenase by Ro 61-8048 or by modulating KMO expression could increase the levels of KA. An increase in KA can inhibit α7nAChRs. (C) Genomic context
of KMO gene located on the forward strand at GRCh38/hg38 genomic coordinates: chr1: 241,531,883-241,595,647 and convergently paired to ncRNA
uncharacterized LOC105373233 locus mapped on reverse strand at genomic coordinates: chr1:241,585,025-241,588,836. The LOC105373233 locus located at
KMO 3′-region complement strand.
CpG Island and Transcription Factor
Binding Sites in KMO Alternative
Promoters
The KMO alternative promoters were investigated for the
presence of CGI. None of the analyzed sequences at 5′-side
of KMO-exon-1 showed CGI. The absence of CGI in the
KMO exon-1 alternative promoters is an indication that these
promoters are hosting TATA-box. The incidence of each of the
18 investigated TFBSs in the 11 KMO alternative promoters is
shown in Supplementary Table S5. Five alternative promoters
host TATA-box, 9 have DTIE motifs, and all promoters were
rich in INR and Oct4 motifs. We investigated whether there are
any statistically significant differences between the three types of
motifs associated with transcription initiation, TATA-box, INR,
and DTIE. As shown in Figure 2, the incidence of TATA-box,
INR, and DTIE motifs varied significantly in the 11 identified
alternative promoters, p< 0.05.
Structural Characteristics of KMO
Promoters
The biophysical properties of DNA can disclose the specific
locations of TFBS and the CGI along regulatory sequences
associated with the process of transcription. We used
dinucleotide scales for measurement of base pairs stacking
energy values, which we found useful to correlate the structural
DNA features with functional sequences, TFBS and CGI, in
the alternative promoters. In this context, we studied the
dinucleotide base pairs stacking energy along 1000 bps sequence
of KMO TRED-2070 (AP1) alternative promoter, which overlaps
with other promoter sequences (Supplementary Table S4). We
observed the promoter characterized by low kcal/mol values, a
type of DNA sequence lacks CGI (Figure 3). Also, our analysis
showed the low kcal/mol values for INR, DTIE, and TATA motifs,
which were within range −6.5 and −7.0 kcal/mol. TATA-box
motif was mapped nearby TSS region that is easily unstacked.
The Potential Function of LOC105373233
in the Regulation of KMO Expression
Figure 4 and Supplementary Table S2 show the CDS of
the KMO gene composed of 1461 bases mapped within the
KMO mRNA transcript, NM_003679.4, composed of 5266 bps.
The primary part of exon-15 is untranslated, which suggested
the critical function played by the KMO 3′-UTR region in
the regulation of KMO expression and imply the presence
of regulatory sequences (Supplementary Table S2). The MRE
in the KMO mRNA is necessary for the miRNA:mRNA
prediction, especially in the 3′ UTR. Knowing that the
ncRNA loci are sources for miR, we investigated the possible
association of the uncharacterized LOC105373233 locus, which
encodes an ncRNA, in the regulation of KMO expression.
We explored the transcripts sequence complementarities of the
two convergent loci. NCBI-Nucleotide database showed one
uncharacterized LOC105373233 ncRNA transcript, XR_949327.1
predicted by automated computational analysis compared to
five transcripts for KMO locus; four predicted and one is
known mRNA transcript. The predicted ncRNA transcript,
namely, LOC105373233 variant transcript XR_949327.1 of 422
bps used in the alignment analysis with KMO mRNA transcript
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FIGURE 2 | The prevalence of the transcription factor binding sites (TFBSs), TATA-box, INR, and DTIE in the KMO alternative promoters. The promoters reported in
the TRED (AP1, AP2), EPD (AP3), and PrESSto/FANTOM5 (AP4-AP11) databases.
FIGURE 3 | The plot of dinucleotide base pairs stacking energy (kcal/mol) measurement for the sequence KMO-TRED 2070 promoter, AP1. TSS, transcription
starting site; INR, DTIE, and TATA, TFBS motifs.
NM_003679.4. We identified a sequence in the transcript
XR_949327.1 composed of 52 bps showed 75% similarity with
the matching KMO NM_003679.4 sequence (Supplementary
Figure S3). The pairwise sequence alignment analysis suggested
the potential formation of a heteroduplex between the 3′-UTR
region of KMO-exon 15 and miR sequence from the ncRNA
LOC105373233 transcript, XR_949327.1. The data in Figure 4
and Supplementary Table S2 also show the matching regions
between LOC105373233 ncRNA and the KMO 3′ UTR region.
Furthermore, we used miRbase tool to detect the presence of the
miR in the ncRNA uncharacterized LOC105373233 transcript,
NCBI Reference Sequence: XR_949327.1. The two identified
miR sequences, referred to by us hsa-LOC105373233-1 and hsa-
LOC105373233-2, are comparable to the human (Homo sapiens)
hsa-miR-5096 and hsa-miR-1285-3p respectively (Table 1). The
identified miR sequences bind target MRE of KMO mRNA
NM_003679.4; the analysis carried out by the RNA22 v2 tool.
The obtained low p-values, 3.89E-1-1.43E-3, an indication of a
higher chance that the KMO mRNA NM_003679.4 contains a
valid MRE.
Identification of Intragenic Promoter
With Potential Bidirectional Activity
We hypothesized the presence of an intragenic promoter in
the overlapping genomic space of KMO in the forward strand
that complements ncRNA uncharacterized LOC105373233 in
reverse strand. We used the Neural Network Promoter Prediction
(Reese, 2001) and Promoter2.0 Prediction Server (Knudsen,
1999) and identified a predicted promoter, which is expected
to be involved in the expression uncharacterized ncRNA
LOC105373233 locus. The predicted promoter includes a highly
likely prediction of TSS with a score of 1.219 shown in
Supplementary Figure S1. We investigated the unique regulatory
features of the identified promoter sequence occupies 1680 bps
in the genomic surroundings up and downstream of the TSS
(Supplementary Figure S1). The promoter’s sequence is located
at chr1:241,585,594-241,587,273 and includes INR, DTIE, HIF,
GATA, and P53 motifs and lacks TATA-box (Supplementary
Table S5). A CGI identified in the identified promoter sequence
(Supplementary Figure S1). The CGI is of 221 nucleotides
located between KMO-exon 11 and KMO-exon 12 mapped at
chr1: 241,587,041-241,587,261. The sequence characterized by
the presence of consensus motifs for DNA binding sites of
a small group of transcription factors found in bidirectional
promoters that included NRF1 and ZNF143, suggesting a
possible bidirectional activity (Supplementary Table S5). The
predicted intragenic promoter with potential bidirectional
activities referred to by us KMO-BD. It remained to provide
experimental evidence for the transcriptional function of the
predicted promoter in the expression of ncRNA LOC105373233
and KMO loci (see section “Discussion”).
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FIGURE 4 | The KMO genomic space showing the CDS sequence of KMO mRNA transcript NM_003679, and the matching sequence of untranslated KMO
exon-15 sequence with LOC105373233 ncRNA mRNA sequence.
TABLE 1 | The miRBase used to search for miR sequences hosted in uncharacterized LOC105373233 ncRNA, NCBI Reference Sequence: XR_949327.1.
miR Leftmost position of predicted target site Heteroduplex p-value
hsa-LOC105373233-1 Position 2464 located at 3′ UTR region of
KMO mRNA
GGCTGGAGTGCAGTGGTGAGAT
| | | | | : | | | | | | | | : | :
CGGACCAGTTGT–ACCACTTTG
1.43E-3
hsa- miR-5096 Position 1444 located at KMO-exon 13 T TCAGAAGAACATGGAGAGAT
| | | | | | | | | | | : | :
CGGACTGGTTGTACCACTTTG
3.89E-1
hsa-miR-5096 Position 2464 located at 3′ UTR region of
KMO mRNA
GGCTGGAGTGCAGTGGTGAGAT
| | | | : : | | | | | | | | : | :
CGGACTGGTTGT–ACCACTTTG
1.43E-3
hsa-LOC105373233-2 Position 1446 located at KMO-exon 13 CAGAAGAACATGGAGAGAT T
| | | | | | | | | : | : :
GACCAGTTGTACCACTTTGG
3.89E-1
hsa-LOC105373233-2 Position 2466 located at 3′ UTR region of
KMO mRNA
CTGGAGTGCAGTGGTGAGATC
| | | | : | | | | | | | | : | : |
GACCAGTTGT–ACCACTTTGG
1.43E-3
hsa-miR-1285-3p Position 2466 located at 3′ UTR region of
KMO mRNA
CTGGAGTGCAGTGGTGAGATC
| | | | : | | : : | | | | | | : |
GACCCGTTGTT–TCACTCTGG
1.43E-3
hsa-miR-1285-3p Position 4661 located at 3′ UTR region of
KMO mRNA
CTGTGCTATAATTAGAGACT
| | | | | | : | | | | | | | :
GACCCGTTGTTTCACTCTGG
2.58E-2
The two identified miR sequences, referred to by us hsa-LOC105373233-1 and hsa-LOC105373233-2, are comparable to the human (Homo sapiens) hsa-miR-5096 and
hsa-miR-1285-3p, respectively. The miR sequences bind and target the MRE of KMO mRNA, NCBI Reference Sequence: NM_003679.4. MRE analysis carried out by the
RNA22 v2 tool. The upper sequence in the heteroduplex represents MRE for KMO mRNA. A low p-value indicates a higher chance that the locus contains a valid MRE.
DISCUSSION
Understanding the molecular basis of nicotine addiction is a
prerequisite to evaluate the effectiveness of protective measures.
Analysis of genes and their regulatory factors associated with
nicotine addiction provides novel molecular approaches to
applying preventive procedures to reduce tobacco smoking harm
by supporting smokers to quit and thwart non-smokers from
smoking. Several genes found unequivocally associated with
nicotine addiction and treatment, namely, CHRNA3, CHRNB4,
CHRNA5, NRXN1, and CYP2A6 (Nussbaum et al., 2008;
Wassenaar et al., 2011; Broms et al., 2012; Chen et al., 2014;
Zhu et al., 2014; Pérez-Rubio et al., 2016). Identifying new
genes can give a new supportive approach to the problem.
Our investigation of KMO locus showed potential use of
novel molecular methods in the treatment of tobacco initiation
and cessation. The KMO gene is pivotal in regulating the
availability of KA (Albuquerque and Schwarcz, 2013; Secci et al.,
2017). The KA is a neuroprotective and immunomodulating
metabolite (Chen and Guillemin, 2009; Bagasrawala et al., 2016;
Wirthgen et al., 2018) and inhibits the α7nAChRs in the CNS
(Albuquerque and Schwarcz, 2013; Secci et al., 2017). Also,
changes in KMO expression or activity may contribute to
the development of neurodegenerative, neuropsychiatric, and
neurodevelopmental diseases (Tan et al., 2012; Parrott and
O’Connor, 2015; Smith et al., 2016). Since the KA exhibits a
poor penetration of the blood-brain barrier (Fukui et al., 1991;
Varga et al., 2016), the modulation of KMO expression by RNA
interference (RNAi) remains of interest to solve the problem
of KA availability in the brain (Mathupala, 2009; Kruspe and
Giangrande, 2017). Thus, investigating the influence of genomic
and epigenomic regulatory factors in KMO expression provides
Frontiers in Genetics | www.frontiersin.org 6 June 2018 | Volume 9 | Article 198
fgene-09-00198 June 11, 2018 Time: 19:8 # 7
Aziz et al. KMO 5′ and 3′-Regulatory Regions
further support to introduce novel personalized medicine
approaches for the treatment of individuals vulnerable to nicotine
initiation and addiction (Chen and Bierut, 2013; Chen L.S. et al.,
2018).
The regulation ofKMO transcription process and involvement
of regulatory elements associated with the process is still
poorly understood. We observed in the genomic databases 11
alternative promoters for this gene with variable expression
activities. Variable expression of a gene in tissues linked to
specific features of the regulatory sequences of the alternative
promoters (Liu and Fischer, 1996; Al-Obaide et al., 2015).
Our bioinformatic analyses supported this assumption and
showed the degree of difference of expression of KMO in
various human tissues including the human brain linked
to the type of KMO alternative promoter engaged in the
transcription process. In this study, we showed the KMO
alternative promoters characterized by the absence of CGI.
Thus, KMO gene is not prone to silencing by CGI methylation
(Deaton and Bird, 2011). A recent study showed that genes
with and without CGI organized as separated clusters within
the genome (Beck et al., 2018). Our thorough analysis of
18 TFBSs revealed three common motifs in the alternative
promoters, TATA-box, INR, and DTIE. The incidence of the
motifs varied significantly in the 11 identified alternative
promoters, p < 0.05. Furthermore, the structural characteristics
of regulatory sequences can affect the transcription process
(Kumar and Bucher, 2016). It is possible to show the difference
in the structure of the regulatory sequences by measurements of
the dinucleotide stacking energy values. The KMO promoters’
sequences showed a co-localized specific pattern of dinucleotide
stacking energy associated with transcription starting site
(TSS) and the TFBS motifs. The dinucleotide stacking energy
can provide approximations regarding the distribution of
TFBSs along the sequences of the KMO alternative promoters.
Also, the measurements of the stacking energy can show the
degree of stability and dissociation patterns of the double helix
along the regulatory sequence. Previous studies showed the
correlation between the specific regulatory sequence and the
range of dinucleotide base-stacking energy (Ornstein et al.,
1978; Al-Obaide et al., 2015), such correlation observed in
the current study. The thermodynamic stability of double-
stranded sequences is of importance for understanding the
molecular details of gene expression (Häse and Zacharias,
2016). We speculate that the structural features might be the
cause of the selective use of one of the alternative promoters
by the gene regulatory machinery that triggers off high
expression of KMO mRNA. We noticed that the p1@KMO1
alternative promoter is more active in the brain compared
with other KMO promoters. It is possible to suggest that
p1@KMO1 is a candidate to lower KMO expression by
suitable silencing methods, for example, RNAi, antisense
oligonucleotides (ASOs), and CRISPR/Cas9 knockdown
(Mathupala, 2009; Kruspe and Giangrande, 2017; Ghosh and
Tabrizi, 2017). However, this conclusion does not exclude the
functions of additional regulatory factors associated with KMO
expression besides alternative promoters, for example, miR and
ncRNAs.
Another significant finding is identification of an intronic
promoter with potential bidirectional activity located at the
3′-region of KMO genomic space, which might take part in
the control of the expression of ncRNA LOC105373233 and
KMO loci. The discovered promoter showed the potential to
guide the transcription of two loci in a convergent configuration.
This type of transcription represented 25% of gene pairs in
fungi (Kensche et al., 2008) and reported in mammals (Tran
et al., 2003). However, transcription in a divergent manner is
the dominant type (Katayama et al., 2005; Engström et al.,
2006; Li et al., 2006; Yang and Elnitski, 2008; Seila et al.,
2009). Most bidirectional promoters are GC rich and exhibit
CGI (Trinklein et al., 2004; Orekhova and Rubtsov, 2013).
Additionally, the bidirectional promoters contain consensus
sequences of DNA binding sites (motifs) of a small group
of transcription factors including NRF1 and ZNF143, while
many known transcription factor consensus binding motifs
are underrepresented in bidirectional promoters (Lin et al.,
2007; Anno et al., 2011). Our analysis showed the predicted
bidirectional promoter hosted CGI and the bidirectional specific
transcription factors motifs, NRF1 and ZNF143. Our data
suggest the possibility of involvement of the identified 3′-
end in the transcription process of KMO from the 3′-end.
Although transcription starts from the 5′ end, there are crosstalk
between mRNA 3′-end processing and transcription initiation
(Mapendano et al., 2010). Also, the 3′-end regions have a unique
and sequence dependent effect on gene expression (Shalem et al.,
2013).
The most significant finding reported in this study is the
potential function of the predicted uncharacterized ncRNA
LOC105373233 locus in the regulation of KMO expression. We
showed the likelihood of formation of RNA-RNA heteroduplexes
between the transcripts of the convergent loci, LOC105373233
ncRNA, and the KMO mRNA 3′ UTR region. Ensembl database
shows the biotype of LOC105373233 is long non-coding RNA
(lncRNA). The lncRNAs are source for various types of miRNAs
(Saini et al., 2007; Dykes and Emanueli, 2017; Chen X. et al.,
2018). In this study, we showed that the LOC105373233
ncRNA NCBI Reference Sequence: XR_949327.1 is the source
of two discovered miR bind target KMO-MRE at 3′ UTR
region. The KMO-MRE position is at the identified RNA-RNA
heteroduplexes region composed of 52 bps. The two types of miRs
are comparable to the human (Homo sapiens) hsa-miR-5096 and
hsa-miR-1285-3p. Our data suggested potential downregulation
of KMO expression by the miR hosted in the convergently
paired uncharacterized ncRNA LOC105373233 locus. However,
if the identified miRNAs deregulated, the KMO escapes miRNA-
mediated repression. The mechanism by which miRNA control
gene expression is a novel sophisticated process. Briefly,
miRNAs are processed from their hairpins and loaded into
the Argonaute (AGO) proteins in effector complexes known as
miRNA-induced silencing complexes (miRISCs). Consequently,
the miRNA serves as a guide for this complex to the target
mRNA where it induces translational repression (Bartel, 2009;
Hausser and Zavolan, 2014; Issler and Chen, 2015). The miRISCs
promote endonucleolytic cleavage of fully complementary
targets or translational repression, mRNA deadenylating, and
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exonucleolytic decay of targets with partial complementarity. It is
believed the primary function of most of the ncRNAs in mammals
downregulating the level of corresponding mRNA expression
(Song et al., 2012; Eades et al., 2014; Uesaka et al., 2014). Also,
ncRNAs are tissue specific (Jiang et al., 2016).
An exciting prospect of our study identification of several
regulatory modes involved in modulation of KMO gene
expression. For instance, the study suggested that the KMO
variable expression is the result of alternative promoters.
The novel finding of this study is the potential role of the
ncRNA uncharacterized LOC105373233 locus in the regulation
of KMO expression. The KMO downregulation by lncRNA
LOC105373233 might increase KA levels that inhibit α7nAChRs.
The data are likely to advance our knowledge about the function
and application of this gene in tobacco smoking cessation and
can have applications for individuals more vulnerable to nicotine
addiction.
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